Aptuit will supply GSK with R&D services from the facilities. The acquisition will allow Aptuit to provide integrated development services to its global customers while keeping the existing pool of life science research experts in Italy.
The financial terms of the deal have not been disclosed.
In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, including depression and pain, to focus on neurodegenerative and neuroinflammatory diseases like Alzheimer's disease, multiple sclerosis and Parkinson's disease. These plans have a direct impact on the Italian R&D facility.
Aptuit specialises in providing contract development and manufacturing services to the pharmaceutical and biotech sectors. This latest acquisition will bring their global portfolio total to 19 locations.
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...